NorthStrive Biosciences Signs Definitive License Agreement for Commercialization of EL-22 and EL-32, a Myostatin-Engineered Probiotic for Muscle Preservation in Animal Health

Core Viewpoint - NorthStrive Biosciences Inc. has entered into a definitive exclusive license agreement with Modulant Biosciences LLC to develop and commercialize animal health products based on its EL-22 and EL-32 assets, marking a significant milestone for the company [1][6]. Group 1: License Agreement Details - The License Agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from EL-22 and EL-32 for non-human animal health applications, excluding the Republic of Korea [2]. - Modulant is responsible for all development, manufacturing, regulatory, and commercialization activities for the licensed products, with a focus on using commercially reasonable efforts [4]. - The agreement includes issued patents, pending patent applications, and associated proprietary know-how related to the EL-22 and EL-32 programs [4]. Group 2: Product and Market Implications - EL-22 and EL-32 target myostatin and activin-A pathways, which are crucial for muscle development, strength, and metabolic efficiency, and are increasingly important in animal health and nutrition applications [3]. - The collaboration aims to advance EL-22 and EL-32-derived products toward commercialization in the growing global animal health market, driven by rising demand for improved animal performance, wellness, and longevity [5]. Group 3: Company Background - NorthStrive Biosciences Inc. focuses on developing cutting-edge aesthetic medicines, with its lead asset EL-22 addressing muscle preservation during weight loss treatments [8]. - PMGC Holdings Inc., the parent company of NorthStrive, is a diversified holding company that seeks growth through strategic acquisitions and investments across various industries [9]. Group 4: Modulant Biosciences Overview - Modulant Biosciences LLC specializes in veterinary medicine innovation, focusing on developing novel drugs and biologics for various animal types, including livestock and companion animals [11].